BioXcel announces new priorities

20 September 2024

US neuroscience company BioXcel Therapeutics (Nasdaq: BTAI) has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501.

The clinical prioritization is intended to optimize resource allocation and focus on the development of BXCL501 in potential new markets, while deprioritizing sales efforts for its approved drug Igalmi (dexmedetomidine) sublingual film.

BioXcel will maintain Igalmi - which was approved in 2022 for the acute treatment of agitation associated with schizophrenia and bipolar disorder - in the market without its current commercial infrastructure.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK